The clinical trial data of Firehawk TES are published in The Lancet * – a world leading medical journal.
It is the first time that The Lancet has published clinical trial data of a Chinese medical device.
It is concluded that Firehawk TES is as safe and effective as the “gold standard” Xience EES stent and the high level of clinical outcome of TARGET AC is confirmed.
TARGET: LESS is MORE
The abluminal groove target eluting design provides MORE level of efficacy and safety with LESS dose of drug, the beauty and merits of a BMS and DES combination.
* The Lancet is a world leading medical journal, currently ranked second out of 154 journals in the Medicine, General & Internal subject category with an impact factor of 53.254 according to the 2017 Journal Citation Reports.
We are proud that since 01 July 2018 our company is an exclusive distributor of MicroPort for selling in Bulgaria and Greece of the world’s first Target eluting stent (TES) –
Firehawk Rapamycin Target Eluting Coronary Stent System.
We are authorized by our partner MicroPort for selling in Bulgaria of the innovative product Firehawk Rapamycin Target Eluting Coronary Stent System – the world’s first Target eluting stent (TES).
You can find more about it in the Products menu of our site.
Since May 2017, our company is certified according to ISO 9001:2015, proof of the standards and the established norms that we observe.
On 01.11.2016 our company joined the members of the Bulgarian Chamber of Commerce and Industry (BCCI).